News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DBV Technologies And CEA Conclude A Scientific Cooperation To Investigate Epigenetic Modulation In Epicutaneous Immunotherapy



4/9/2014 8:49:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BAGNEUX, France, April 9, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of ViaskinĀ®, a new paradigm for the treatment of allergies, announced today a research collaboration agreement with the French National Genotyping Center (CNG) at the French Alternative energies and atomic energy commission (CEA). Dr. J. Tost's team at CNG uses novel technologies to analyze gene regulation and epigenetics, specifically DNA methylation. DBV and CEA/CNG will collaborate to characterize the epigenetic modifications induced by DBV's proprietary epicutaneous immunotherapy (EPITTM). The overall goal of the research is to understand the treatment maintenance effect over time and the predictive value of response to EPITTM treatment using Viaskin.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES